EnWave Corporation · TSXV:ENW
EnWave — Investor Presentation (April 2007)
22 slides from EnWave's investor presentation, Apr 16, 2007
Slide 1: Creating a new generation of dry vaccines and novel tissue engineering products
Creating a new generation of dry vaccines and novel tissue engineering products Investor Presentation
Slide 2: Corporate Overview
Corporate Overview EnWave is a spin off company from the University of British Columbia where it has developed innovative and proprietary technologies to process biomedical material.
Slide 3: EnWave History
EnWave History • 1996-2004: Initial business focus on food dehydration using vacuum microwave technology (nutraREV) • 2005-2006: Designed bioREV technology and initiated UBC research in tissue engineering and dry vaccine applications • 2007: Corporate decision to focus future strategy in the biotech
Slide 4: bioREV
bioREV Processing biological materials with novel & proprietary technology Combine Radiant Microwave Energy with Vacuum to alter physical structures, dehydrate materials, and drive chemical reactions
Slide 5: bioREV Advantages
bioREV Advantages Create novel products with body-friendly material • Flexible input: – Work with a variety of gels and liquids, depending on application – Minimize processing damage to live organisms or sensitive biological materials (e.g. DNA, proteins, antibodies and microbial therapeutics) • Fle
Slide 6: bioREV Advantages
bioREV Advantages Compare with freeze-drying or spray-drying • Fewer processing steps • Rapid (minutes instead of hours or days) • Lower processing costs • Reduced energy consumption • Lower capital cost
Slide 7: Proprietary Technology
Proprietary Technology bioREV Patents Title Ownership Inventors Status of Patent Patent application filed, UBC Dr. Tim PCT reviewed and Production of dry (Exclusively Durance and published. National filing sponges and foams licensed to other UBC initiated in US, Canada, from hydrocolloids EnWave) Re
Slide 8: bioREV Revenue Sources
bioREV Revenue Sources Multiple sources of revenue • Product royalties • Patent product extension • License fees • Process sales – • Exclusivity fees Industry partner
Slide 9: Market Opportunities
Market Opportunities bioREV commercialization focus • Dry Vaccines: Dehydrate vaccines to eliminate cold storage and administer without needles • Tissue Engineering: Create porous bone scaffolds incorporating leading edge drug delivery methods to encourage bone regeneration
Slide 10: bioREV for Dry Vaccines
bioREV for Dry Vaccines Vaccine market has major unmet needs • Storage and delivery costs are key issues for both bio-defense and third-world • Rapid market growth needed to prevent infectious diseases (Avian Flu, West Nile, SARS) and treat illness (HIV, Cancer) • World vaccine market exceeded US$10
Slide 11: bioREV for Dry Vaccines
bioREV for Dry Vaccines Current industry challenges and bioREV solutions Challenges bioREV Solution Thermostable dry powders are less Expensive “cold-chain” required to ship expensive to produce and more reliable and store liquid vaccines to store Dry formulations require new vaccine Dry vaccines ar
Slide 12: bioREV for Tissue Engineering
bioREV for Tissue Engineering New materials for aging bodies • Tissue engineering provides biological substitutes which restore and improve the functions of living tissues • World market for tissue engineering products was USB$125 in 2003; market for bone scaffolds is estimated at USB$5 in 2007
Slide 13: bioREV for Tissue Engineering
bioREV for Tissue Engineering Initial focus is porous bone scaffolds • Bone scaffold: an artificial structure supporting three dimensional tissue formation for the repair or replacement of bone • Requires porous structural material combined with growth compounds, drugs, antibiotics or stem cells • E
Slide 14: bioREV for Tissue Engineering
bioREV for Tissue Engineering Industry challenges and bioREV solution Challenges bioREV Solution bioREV process creates a chemical Difficult to create porous structures using reaction, converting many different types biomaterials that are both biodegradable of biomaterial gels into hard porous and b
Slide 15: bioREV for Tissue Engineering
bioREV for Tissue Engineering Flexible technology also offers other market possibilities Bone graft substitutes: • Eliminate infection risk from human tissue banks during the repair of fractured or defective bones by using synthetic bone graft materials • bioREV has successfully processed a number o
Slide 16: bioREV Commercialization
bioREV Commercialization Four-phase implementation plan • Phase 1: Collaboration Use bioREV for independent studies to expand scientific data; file additional patents • Phase 2: Technology Development & Regulatory Confirm bioREV commercial potential; test pilot units; complete regulatory filings, pr
Slide 17: Aridis Pharmaceuticals
Aridis Pharmaceuticals Implementing the Business Plan • Aridis principals came from MedImmune where they managed technology development and clinical trials for leading edge dry nasal vaccine, “FluMist” • Aridis is focused on developing vaccine formulations using innovative dry delivery methods • Let
Slide 18: Key Objectives for 2007
Key Objectives for 2007 Moving towards commercialization 1. Secure financing to support product development programs 2. Initiate design engineering and regulatory work required to commercialize bioREV equipment in biotechnology industry 3. Sign collaboration agreement with Aridis Pharmaceuticals and
Slide 19: Senior Management
Senior Management Two heads are better than one! Dr. Tim Durance: Chairman & Co-CEO Tim is a founder of EnWave and a Professor and Director of the Food, Nutrition and Health Program at UBC. He has a PhD in Food Science from UBC and is co-inventor of EnWave’s bioREV and nutraREV technologies. John Mc
Slide 20: Capital Structure
Capital Structure As of April, 2007 Type of Security Total Outstanding Common Shares 29,510,240 Warrants 2,433,000 Options 4,900,000 TOTAL: 36,843,240 LISTING:
Slide 21: Investment Highlights
Investment Highlights An attractive investment opportunity • Multiple large market potential • Commercialization potential within 3 to 5 years • Proprietary & novel technology capable of redefining competitive landscape • University of British Columbia support • Experienced management team
Slide 22: Contact Details
Contact Details Mr. John McNicol President & Co-CEO, EnWave Corporation Suite 2000 – 1066 West Hastings St. Vancouver, BC V6E 3X2 Phone: (604) 601-8524 Cell: (604) 603-2959 Email: john.mcnicol@enwave.net Website: www.enwave.net